TICKERNERD
Menu
CORTCORTHealthcare · Biotechnology

CORT Stock Forecast: Corcept Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$123
+0.81% on the day

The 5 Wall Street analysts covering Corcept Therapeutics, Inc. hold a median 12-month price target of $164 — +33.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$13.2B
Ticker Nerd rank
80 / 100
Median analyst target
$164
Analysts covering
5
Revenue$256.1M+31.7% y/y
Operating income$41.3M
Net income$43.0M
Free cash flow$31.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.2%
1M
+29.2%
YTD
+254.1%
1Y
+75.2%
From 52W high
0.0%
From 52W low
+283.3%
$32
$123
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CORT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Corcept Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
80 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
95
Revisions
90
Quality
84
Volatility
74
Momentum
74
Growth
48
Issuance
42
Accruals
42
Size
13

Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (42): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CORT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CORT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150Oct 25Jan 26Apr 26Jul 26CORTHigh $165Median $164Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy0 Hold1 Sell
Low $50Median $164High $165

The green dot is the last close — the median target sits +33.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
30 July 2026Canaccord GenuityMaintainsBuy$150 → $161
30 July 2026HC Wainwright & Co.MaintainsBuy$95 → $165
30 July 2026Piper SandlerReiteratesOverweight$88 → $165
29 July 2026Canaccord GenuityMaintainsBuy$135 → $150
27 July 2026Wolfe ResearchDowngradeUnderperform$50
28 May 2026Canaccord GenuityMaintainsBuy—
28 May 2026Canaccord GenuityMaintainsBuy$110 → $135
28 May 2026HC Wainwright & Co.MaintainsBuy$75 → $95
28 May 2026HC Wainwright & Co.MaintainsBuy—
13 May 2026UBSUpgradeBuy—
4 May 2026HC Wainwright & Co.MaintainsBuy—
1 May 2026Piper SandlerMaintainsOverweight—
26 Mar 2026Canaccord GenuityMaintainsBuy—
26 Mar 2026Wolfe ResearchUpgradePeer Perform—
25 Mar 2026HC Wainwright & Co.MaintainsBuy—
25 Feb 2026HC Wainwright & Co.MaintainsBuy—
20 Feb 2026HC Wainwright & Co.MaintainsBuy—
23 Jan 2026Canaccord GenuityMaintainsBuy—
23 Jan 2026HC Wainwright & Co.MaintainsBuy—
2 Jan 2026Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CORT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CORT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Corcept Therapeutics, Inc. returned +75.2% against +19.6% for the S&P 500, dividends included.

CORT vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Oct 25Jan 26Apr 26Jul 26CORTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CORT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+350.3%
Analysts raising
1
Analysts cutting
0
Fundamentals

Corcept Therapeutics, Inc. (CORT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
271.7×

Cheaper than 3% of US stocks

Price / sales
15.9×

Cheaper than 11% of US stocks

Price / book
18.7×

Cheaper than 6% of US stocks

EV / EBITDA
1597.8×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
31.7%

Higher than 79% of US stocks

Earnings growth (YoY)
22.3%

Higher than 61% of US stocks

Gross margin
98.4%

Higher than 99% of US stocks

Operating margin
16.1%

Higher than 74% of US stocks

Net margin
6.6%

Higher than 64% of US stocks

Returns & dividend
Return on equity
8.2%

Higher than 59% of US stocks

Return on assets
0.5%

Higher than 45% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Corcept Therapeutics, Inc. (CORT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Corcept Therapeutics, Inc. has a market value of $13.2B and an enterprise value of $12.9B.

  • Revenue in the twelve months to 30 June 2026: $830.8M. The latest quarter grew 31.7% year on year.

  • Net income over the same four quarters: $55.2M, a 6.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.42.

  • Free cash flow in the twelve months to 30 June 2026: $106.9M.

  • Shares outstanding: 107.9M.

  • Trailing P/E: 271.7×; forward P/E: 27.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Corcept Therapeutics, Inc. employs 730 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

CORT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CORTCorcept Therapeutics, Inc.$13.2B
80
BMRNBioMarin Pharmaceutical, Inc.$12.9B
60
HALOHalozyme Therapeutics, Inc.$12.3B
97
EXELExelixis, Inc.$14.0B
99
ARWRArrowhead Pharmaceuticals, Inc.$12.2B
59
MDGLMadrigal Pharmaceuticals, Inc.$11.9B
69
TECHBio-Techne Corp.$11.3B
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Corcept Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CORT news & analysis

Like The Knick's, Corcept Rebounded And Is Crushing It

Seeking Alpha · 21 Aug 2026positive

A Seeking Alpha article describes Corcept Therapeutics as having rebounded and performing strongly, citing a Strong Buy rating and revenue and margin growth. It highlights Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth as underpinning the company's revenue expansion and gross margins.

Why it matters — CORT watchers would care because the article points to strong commercial performance from Lifyorli and Korlym as key drivers of the company's recent growth and financial strength.

Trump is up 230% on this stock trade since March

Finbold · 18 Aug 2026positive

President Donald Trump disclosed a position in Corcept Therapeutics (NASDAQ: CORT) on March 4, when the pharmaceutical company was trading at $35.69. The headline notes Trump is up 230% on this stock trade since March.

Why it matters — A CORT watcher would care because a disclosed presidential position in the company highlights notable attention on the stock and its significant price movement since March.

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

Zacks Investment Research · 5 Aug 2026positive

Zacks Investment Research, via its Style Scores system, highlights Corcept Therapeutics (CORT) as a top momentum stock for the long term. The article positions CORT as a strong, market-beating pick for investment portfolios.

Why it matters — A CORT watcher would care because the item frames the company as a leading momentum stock for long-term investors based on Zacks' screening methodology.

Raised Guidance Lifts Corcept to 52-Week High

FXEmpire · 5 Aug 2026positive

Corcept Therapeutics raised its guidance, which lifted the company's stock to a 52-week high. Corcept discovers, develops, and sells medications for severe metabolic, oncologic, and psychiatric disorders, focusing on the hormone cortisol and Cushing's syndrome.

Why it matters — A stock-reach of a 52-week high on raised guidance signals an improved near-term outlook that CORT watchers would track closely.

Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It

Seeking Alpha · 31 July 2026neutral

LIFYORLI generated $47.6 million in its first full quarter, with management targeting $1 billion or more in U.S. peak revenue. However, the analyst notes that the strong launch and clinical demand are already reflected in Corcept's premium valuation, while non-LIFYORLI pipeline assets remain speculative.

Why it matters — A CORT watcher would care because the piece highlights that while LIFYORLI shows blockbuster potential, the stock's current valuation may already price in that success, and the rest of the pipeline is unproven.

FAQ

Frequently asked questions about CORT stock

What is the CORT stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Corcept Therapeutics, Inc. have a median 12-month price target of $164, with estimates ranging from $50 to $165. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CORT stock a buy right now?

Of the 5 analysts covering Corcept Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Corcept Therapeutics, Inc. 80 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CORT?

As at 22 Aug 2026, Corcept Therapeutics, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).

Will CORT stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +33.1% from the last close, and Ticker Nerd's factor model ranks Corcept Therapeutics, Inc. 80 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CORT stock forecast for 2030?

No analyst covering Corcept Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CORT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $165 over the next 12 months.

How has CORT stock performed over the past year?

Corcept Therapeutics, Inc. returned +75.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Corcept Therapeutics, Inc. do?

Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing medications that address severe endocrine, metabolic, oncologic, and neurologic disorders. The company’s core scientific approach is based on modulating the effects of the hormone cortisol, which plays a central role in multiple disease pathways.

What is the latest news on CORT?

The most recent item we track (Seeking Alpha, 21 Aug 2026): "Like The Knick's, Corcept Rebounded And Is Crushing It". A Seeking Alpha article describes Corcept Therapeutics as having rebounded and performing strongly, citing a Strong Buy rating and revenue and margin growth. It highlights Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth as underpinning the company's revenue expansion and gross margins.

Company

About Corcept Therapeutics, Inc.

Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing medications that address severe endocrine, metabolic, oncologic, and neurologic disorders. The company’s core scientific approach is based on modulating the effects of the hormone cortisol, which plays a central role in multiple disease pathways. Corcept Therapeutics today develops therapies for conditions such as hypercortisolism and is evaluating compounds in clinical settings for advanced ovarian and prostate cancers, amyotrophic lateral sclerosis (ALS), and metabolic dysfunction-associated steatohepatitis (MASH). Its portfolio is centered on proprietary cortisol modulators designed to offer targeted treatment options where existing therapies may be limited. Corcept Therapeutics markets its products primarily to healthcare providers and specialty treatment centers managing complex endocrine and oncologic conditions. Founded in 1998 and headquartered in Redwood City, California, the company operates within the broader health technology and major pharmaceuticals industry, contributing specialized expertise in cortisol biology to address serious, difficult-to-treat diseases.

CEO Dr. Joseph K. Belanoff M.D. · 730 employees · United States · https://www.corcept.com